DC-Y13-27
DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (KD: 37.9 μM) . DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer[1][2][3].
Product Specifications
UNSPSC
12352005
Target
FOXO; Interleukin Related; MMP; Pyroptosis; YTHDF
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; Immunology/Inflammation; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/dc-y13-27.html
Purity
99.52
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
N#C/C(C(N)=O)=C\C1=CC=C(C2=CC(O)=CC=C2)S1
Molecular Formula
C14H10N2O2S
Molecular Weight
270.31
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
FOXO3; IL-1; MMP-1; MMP-3; MMP-7; MMP-9; YTHDF2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
